The global Hairy Cell Leukemia (HCL) Drug Indsutry is poised for substantial expansion, fueled by breakthroughs in precision oncology and a rising patient demographic. A new market study reveals that the sector, focused on treating this rare but chronic B-cell malignancy, is moving rapidly toward next-generation therapeutic approaches that promise durable remission and improved...